A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI.
A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI.
复制标题
DOI：
10.1371/journal.pone.0028092
复制
发表时间：
2011
期刊：
影响因子：
3.7
通讯作者：
Alzheimer's Disease Neuroimaging Initiative
中科院分区：
文献类型：
--
作者：
O'Bryant SE;Xiao G;Barber R;Huebinger R;Wilhelmsen K;Edwards M;Graff-Radford N;Doody R;Diaz-Arrastia R;Texas Alzheimer's Research & Care Consortium;Alzheimer's Disease Neuroimaging Initiative
目前还没有一种快速且具有成本效益的工具可以作为人群水平上阿尔茨海默病（AD）的一线筛查工具。生成并交叉验证基于血液的AD筛选器，该筛选器在血清和血浆中均产生可接受的准确度。对来自德克萨斯州阿尔茨海默病研究联盟（TARC）的197名阿尔茨海默病（AD）参与者和199名对照参与者进行血清生物标志物蛋白的分析，并对来自阿尔茨海默病神经成像倡议（ADNI）的112名AD和52名对照参与者的血浆蛋白进行进一步分析。完整的算法来自生物标志物风险评分，临床实验室（葡萄糖，甘油三酯，总胆固醇，同型半胱氨酸）和人口统计学（年龄，性别，教育，APOE*E4状态）数据。老年痴呆症11种蛋白质符合我们的标准，并用于生物标志物风险评分。来自TARC血清样品（训练集）的随机森林（RF）生物标志物风险评分在ADNI血浆样品（训练集）中产生了足够的准确性（AUC = 0.70，灵敏度（SN）= 0.54和特异性（SP）= 0.78），低于从ADNI脑脊液（CSF）分析中获得的准确性（t-tau/Aβ比值AUC = 0.92）。 然而，完整算法产生了极好的准确度（AUC = 0.88，SN = 0.75，SP = 0.91）。 基于阳性检测结果（LR+）患有AD的似然比= 7.03（SE = 1.17; 95%CI = 4.49-14.47），基于算法（LR-）未患有AD的似然比= 3.55（SE = 1.15; 2.22-5.71），ADNI队列中计算的AD比值比（OR）= 28.70（1.55; 95%CI = 11.86-69.47）。 有可能创建一种基于血液的筛查算法，该算法适用于血清和血浆，提供与CSF分析相当的筛查准确度。
There is no rapid and cost effective tool that can be implemented as a front-line screening tool for Alzheimer's disease (AD) at the population level. To generate and cross-validate a blood-based screener for AD that yields acceptable accuracy across both serum and plasma. Analysis of serum biomarker proteins were conducted on 197 Alzheimer's disease (AD) participants and 199 control participants from the Texas Alzheimer's Research Consortium (TARC) with further analysis conducted on plasma proteins from 112 AD and 52 control participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The full algorithm was derived from a biomarker risk score, clinical lab (glucose, triglycerides, total cholesterol, homocysteine), and demographic (age, gender, education, APOE*E4 status) data. Alzheimer's disease. 11 proteins met our criteria and were utilized for the biomarker risk score. The random forest (RF) biomarker risk score from the TARC serum samples (training set) yielded adequate accuracy in the ADNI plasma sample (training set) (AUC = 0.70, sensitivity (SN) = 0.54 and specificity (SP) = 0.78), which was below that obtained from ADNI cerebral spinal fluid (CSF) analyses (t-tau/Aβ ratio AUC = 0.92). However, the full algorithm yielded excellent accuracy (AUC = 0.88, SN = 0.75, and SP = 0.91). The likelihood ratio of having AD based on a positive test finding (LR+) = 7.03 (SE = 1.17; 95% CI = 4.49–14.47), the likelihood ratio of not having AD based on the algorithm (LR−) = 3.55 (SE = 1.15; 2.22–5.71), and the odds ratio of AD were calculated in the ADNI cohort (OR) = 28.70 (1.55; 95% CI = 11.86–69.47). It is possible to create a blood-based screening algorithm that works across both serum and plasma that provides a comparable screening accuracy to that obtained from CSF analyses.
登录
查看更多内容
在早期发现阿尔茨海默氏病时，磁共振成像可改善脑脊液生物标志物。
DOI：
10.3233/jad-2009-0968
发表时间：
2009
期刊：
Journal of Alzheimer's disease : JAD
影响因子：
--
作者：
Brys M;Glodzik L;Mosconi L;Switalski R;De Santi S;Pirraglia E;Rich K;Kim BC;Mehta P;Zinkowski R;Pratico D;Wallin A;Zetterberg H;Tsui WH;Rusinek H;Blennow K;de Leon MJ
通讯作者：
de Leon MJ
影响因子：
3.9
作者：
Ewers, Michael;Mielke, Michelle M.;Hampel, Harald
通讯作者：
Hampel, Harald
影响因子：
2.7
作者：
Komulainen, Pirjo;Pedersen, Maria;Rauramaa, Rainer
通讯作者：
Rauramaa, Rainer
影响因子：
2.5
作者：
AKIYAMA, H;IKEDA, K;MCGEER, PL
通讯作者：
MCGEER, PL
影响因子：
12.7
作者：
Hu, William T.;Chen-Plotkin, Alice;Trojanowski, John Q.
通讯作者：
Trojanowski, John Q.